{"title":"Alpha1-antitrypsin deficiency: An updated review","authors":"Jean-François Mornex , Julie Traclet , Olivier Guillaud , Magali Dechomet , Christine Lombard , Mathias Ruiz , Didier Revel , Philippe Reix , Vincent Cottin","doi":"10.1016/j.lpm.2023.104170","DOIUrl":"10.1016/j.lpm.2023.104170","url":null,"abstract":"<div><p><span>Alpha1-antitrypsin deficiency (AATD) is a rare autosomal recessive disease associated with the homozygous Z variant of the </span><em>SERPINA1</em><span> gene. Clinical expression of AATD, reported 60 years ago associate a severe deficiency, pulmonary emphysema<span><span> and/or liver fibrosis. Pulmonary </span>emphysema is due to the severe alpha1-antitrypsin deficiency of the </span></span><em>ZZ</em> homozygous status and is favored by smoking. Liver fibrosis is due to the <em>ZZ</em><span> homozygous status and is favored by obesity and excessive chronic alcohol intake, with a risk of liver cancer. Diagnosis is based on serum level and either isoelectric focusing determination of the biochemical phenotype or PCR detection of some variants. </span><em>SERPINA1</em><span><span><span> gene sequencing is necessary in case of discrepancies between the results of these tests. No treatment is available for the liver disease in AATD. Although no specific trial has been performed, </span>COPD<span><span> in AATD should be treated as per COPD recommendations. Based on a randomized clinical trial, augmentation therapy is indicated in non-smoking adults less than 70 years of age with emphysema at chest CT, confirmed homozygous AATD, and FEV1 between 35% and 70% of predicted. In contrast Z </span>heterozygosis (MZ or SZ) brings a risk of lung or liver disease only in association with further risk factors. Early detection, in all patients with COPD and </span></span>chronic liver disease, is critical for the correct information of Z variant carriers. News ways of correcting the liver production of alpha1-antitrypsin will modify the care of AATD patients.</span></p></div>","PeriodicalId":20530,"journal":{"name":"Presse Medicale","volume":"52 3","pages":"Article 104170"},"PeriodicalIF":2.7,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10137364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Presse MedicalePub Date : 2023-09-01DOI: 10.1016/j.lpm.2023.104171
Johanna Raidt , Niki Tomas Loges , Heike Olbrich, Julia Wallmeier, Petra Pennekamp , Heymut Omran
{"title":"Primary ciliary dyskinesia","authors":"Johanna Raidt , Niki Tomas Loges , Heike Olbrich, Julia Wallmeier, Petra Pennekamp , Heymut Omran","doi":"10.1016/j.lpm.2023.104171","DOIUrl":"10.1016/j.lpm.2023.104171","url":null,"abstract":"<div><h3>Background and objectives</h3><p><span>Primary ciliary dyskinesia (PCD, ORPHA:244) is a group of rare genetic disorders characterized by dysfunction of </span>motile cilia<span>. It is phenotypically and genetically heterogeneous, with more than 50 genes involved. Thanks to genetic, clinical, and functional characterization, immense progress has been made in the understanding and diagnosis of PCD. Nevertheless, it is underdiagnosed due to the heterogeneous phenotype and complexity of diagnosis. This review aims to help clinicians navigate this heterogeneous group of diseases. Here, we describe the broad spectrum of phenotypes associated with PCD and address pitfalls and difficult-to-interpret findings to avoid misinterpretation.</span></p></div><div><h3>Method</h3><p>Review of literature</p></div><div><h3>Conclusion</h3><p>PCD diagnosis is complex and requires integration of history, clinical picture, imaging, functional and structural analysis of motile cilia and, if available, genetic analysis to make a definitive diagnosis. It is critical that we continue to expand our knowledge of this group of rare disorders to improve the identification of PCD patients and to develop evidence-based therapeutic approaches.</p></div>","PeriodicalId":20530,"journal":{"name":"Presse Medicale","volume":"52 3","pages":"Article 104171"},"PeriodicalIF":2.7,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10142488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Presse MedicalePub Date : 2023-09-01DOI: 10.1016/j.lpm.2023.104166
Thomas Koudstaal, Marlies S. Wijsenbeek
{"title":"Idiopathic pulmonary fibrosis","authors":"Thomas Koudstaal, Marlies S. Wijsenbeek","doi":"10.1016/j.lpm.2023.104166","DOIUrl":"10.1016/j.lpm.2023.104166","url":null,"abstract":"<div><p>Idiopathic pulmonary fibrosis (IPF) is a progressive devastating lung disease with substantial morbidity. It is associated with cough, dyspnea and impaired quality of life. If left untreated, IPF has a median survival of 3 years.</p><p>IPF affects ∼3 million people worldwide, with increasing incidence in older patients. The current concept of pathogenesis is that pulmonary fibrosis results from repetitive injury to the lung epithelium, with fibroblast accumulation, myofibroblast activation, and deposition of matrix. These injuries, in combination with innate and adaptive immune responses, dysregulated wound repair and fibroblast dysfunction, lead to recurring tissue remodeling and self-perpetuating fibrosis as seen in IPF.</p><p>The diagnostic approach includes the exclusion of other interstitial lung diseases or underlying conditions and depends on a multidisciplinary team-based discussion combining radiological and clinical features and well as in some cases histology. In the last decade, considerable progress has been made in the understanding of IPF clinical management, with the availability of two drugs, pirfenidone and nintedanib, that decrease pulmonary lung function decline. However, current IPF therapies only slow disease progression and prognosis remains poor. Fortunately, there are multiple clinical trials ongoing with potential new therapies targeting different disease pathways.</p><p>This review provides an overview of IPF epidemiology, current insights in pathophysiology, diagnostic and therapeutic management approaches. Finally, a detailed description of current and evolving therapeutic approaches is also provided.</p></div>","PeriodicalId":20530,"journal":{"name":"Presse Medicale","volume":"52 3","pages":"Article 104166"},"PeriodicalIF":2.7,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9877518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Presse MedicalePub Date : 2023-09-01DOI: 10.1016/j.lpm.2023.104172
Marc Humbert , Thomas Wagner
{"title":"The European reference network on rare lung diseases (ERN-LUNG) ambition to offer better lung health for all","authors":"Marc Humbert , Thomas Wagner","doi":"10.1016/j.lpm.2023.104172","DOIUrl":"10.1016/j.lpm.2023.104172","url":null,"abstract":"","PeriodicalId":20530,"journal":{"name":"Presse Medicale","volume":"52 3","pages":"Article 104172"},"PeriodicalIF":2.7,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10277632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Presse MedicalePub Date : 2023-09-01DOI: 10.1016/j.lpm.2023.104174
Miguel Barbosa, James D. Chalmers
{"title":"Bronchiectasis","authors":"Miguel Barbosa, James D. Chalmers","doi":"10.1016/j.lpm.2023.104174","DOIUrl":"10.1016/j.lpm.2023.104174","url":null,"abstract":"<div><p>Bronchiectasis is a final common pathway of a wide variety of underlying conditions including infectious, autoimmune, allergic, genetic and inflammatory conditions. Patients experience a chronic disease with variable clinical symptoms and course, but most experience cough, sputum production and recurrent exacerbations. Symptoms of bronchiectasis lead to poor quality of life and exacerbations are the major driver of morbidity and mortality. Patients are often chronically infected with bacteria with the most common being <em>Pseudomonas aeruginosa</em> and <em>Haemophilus influenzae</em>. Treatment of bronchiectasis includes standardised testing to identify the underlying cause with targeted treatment if immune deficiency, allergic bronchopulmonary aspergillosis or non-tuberculous mycobacterial infection, for example, are identified. Airway clearance is the mainstay of therapy for patients with symptoms of cough and sputum production. Frequently exacerbating patients may benefit from long term antibiotic or mucoactive therapies. Bronchiectasis is a heterogeneous disease and increasingly precision medicine approaches are advocated to target treatments most appropriately and to limit the emergence of antimicrobial resistance.</p></div>","PeriodicalId":20530,"journal":{"name":"Presse Medicale","volume":"52 3","pages":"Article 104174"},"PeriodicalIF":2.7,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41148274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Lymphangioleiomyomatosis","authors":"Davide Elia , Roberto Cassandro , Antonella Caminati , Francesca Luisi , Sergio Harari","doi":"10.1016/j.lpm.2023.104173","DOIUrl":"10.1016/j.lpm.2023.104173","url":null,"abstract":"<div><p><span><span>Lymphangioleiomyomatosis (LAM) is an ultra-rare, slowly progressive neoplastic cystic disease, belonging to the group of PEComas. It can occur sporadically or associated to </span>tuberous sclerosis complex disease and affects mainly women in child-birth age. Dyspnoea is the most frequent symptom referred to the time of diagnosis, however </span>spontaneous pneumothorax<span> may be a typical presentation associated to extrathoracic manifestations, such as renal angiomyolipomas<span>. In the last decade, important advances in understanding molecular mechanisms underlying the LAM pathogenesis have been reached. It has allowed to obtain improvements in the research of novel biomarkers, treatment and a better management of the disease.</span></span></p></div>","PeriodicalId":20530,"journal":{"name":"Presse Medicale","volume":"52 3","pages":"Article 104173"},"PeriodicalIF":2.7,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10203620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Presse MedicalePub Date : 2023-09-01DOI: 10.1016/j.lpm.2023.104169
Isabelle Fajac , Pierre-Régis Burgel
{"title":"Cystic fibrosis","authors":"Isabelle Fajac , Pierre-Régis Burgel","doi":"10.1016/j.lpm.2023.104169","DOIUrl":"10.1016/j.lpm.2023.104169","url":null,"abstract":"<div><p><span><span><span>Cystic fibrosis (CF) is an </span>autosomal recessive genetic disease caused by variants in the gene encoding for the </span>cystic fibrosis transmembrane conductance regulator<span><span> (CFTR) protein. CFTR dysfunction results in abnormal chloride and bicarbonate transport in epithelial cells, leading to a </span>multiorgan disease dominated by respiratory and digestive manifestations. The respiratory disease, which is characterized by airway </span></span>mucus<span><span> plugging, chronic bacterial infection and progressive development of bronchiectasis, may lead to </span>chronic respiratory failure<span>, which is the main cause of premature death in people with CF. Over the past 50 years, major progress has been obtained by implementing multidisciplinary care, including nutritional support, airway clearance<span> techniques and antibiotics in specialized CF centers. The past 10 years have further seen the progressive development of oral medications, called CFTR modulators, that partially restore ion transport and lead to a major improvement in clinical manifestations and lung function, presumably resulting in longer survival. Although an increasing proportion of people with CF are being treated with CFTR modulators, challenges remain regarding access to CFTR modulators due to their high cost, and their lack of marketing approval and/or effectiveness in people with rare CFTR variants. The anticipated increase in the number of adults with CF and their aging also challenge the current organization of CF care. The purpose of this review article is to describe current status and future perspective of CF disease and care.</span></span></span></p></div>","PeriodicalId":20530,"journal":{"name":"Presse Medicale","volume":"52 3","pages":"Article 104169"},"PeriodicalIF":2.7,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10142490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Presse MedicalePub Date : 2023-09-01DOI: 10.1016/j.lpm.2023.104168
Athénaïs Boucly , Christian Gerges , Laurent Savale , Xavier Jaïs , Mitja Jevnikar , David Montani , Olivier Sitbon , Marc Humbert
{"title":"Pulmonary arterial hypertension","authors":"Athénaïs Boucly , Christian Gerges , Laurent Savale , Xavier Jaïs , Mitja Jevnikar , David Montani , Olivier Sitbon , Marc Humbert","doi":"10.1016/j.lpm.2023.104168","DOIUrl":"10.1016/j.lpm.2023.104168","url":null,"abstract":"<div><p><span><span>Pulmonary arterial hypertension (PAH) is a rare and progressive disease characterised by remodelling of the pulmonary arteries and progressive narrowing of the pulmonary vasculature<span>. This leads to a progressive increase in pulmonary vascular resistance and </span></span>pulmonary arterial pressure<span> and, if left untreated, to right ventricular failure and death. A correct diagnosis requires a complete work-up including right </span></span>heart catheterisation performed in a specialised centre.</p><p><span><span>Although our knowledge of the epidemiology<span>, pathology and pathophysiology of the disease, as well as the development of innovative therapies, has progressed in recent decades, PAH remains a serious clinical condition. Current </span></span>treatments<span> for the disease target the three specific pathways of endothelial dysfunction that characterise PAH: the </span></span>endothelin<span>, nitric oxide<span> and prostacyclin pathways.</span></span></p><p><span>The current treatment algorithm is based on the assessment of severity using a multiparametric risk stratification approach at the time of diagnosis (baseline) and at regular follow-up visits. It recommends the initiation of combination therapy in PAH patients without cardiopulmonary comorbidities. The choice of therapy (dual or triple) depends on the initial severity of the condition. The main treatment goal is to achieve low-risk status. Further escalation of treatment is required if low-risk status is not achieved at subsequent follow-up assessments. In the most severe patients, who are already on maximal medical therapy, </span>lung transplantation may be indicated.</p><p>Recent advances in understanding the pathophysiology of the disease have led to the development of promising emerging therapies targeting dysfunctional pathways beyond endothelial dysfunction, including the TGF-β and PDGF pathways.</p></div>","PeriodicalId":20530,"journal":{"name":"Presse Medicale","volume":"52 3","pages":"Article 104168"},"PeriodicalIF":2.7,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10137362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Presse MedicalePub Date : 2023-06-01DOI: 10.1016/j.lpm.2022.104162
Ariane Lewis
{"title":"International variability in the diagnosis and management of disorders of consciousness","authors":"Ariane Lewis","doi":"10.1016/j.lpm.2022.104162","DOIUrl":"10.1016/j.lpm.2022.104162","url":null,"abstract":"<div><p>This manuscript explores the international variability in the diagnosis and management of disorders of consciousness (DoC). The identification, evaluation, intervention, exploration, prognostication and limitation of therapy for patients with DoC is reviewed through an international lens. The myriad factors that impact the diagnosis and management of DoC including 1) financial, 2) legal and regulatory, 3) cultural, 4) religious and 5) psychosocial considerations are discussed. As data comparing patients with DoC internationally are limited, findings from the general critical care or neurocritical care literature are described when information specific to patients with DoC is unavailable.</p><p>There is a need for improvements in clinical care, education, advocacy and research related to patients with DoC worldwide. It is imperative to standardize methodology to evaluate consciousness and prognosticate outcome. Further, education is needed to 1) generate awareness of the impact of the aforementioned considerations on patients with DoC and 2) develop techniques to optimize communication about DoC with families. It is necessary to promote equity in access to expertise and resources for patients with DoC to enhance the care of patients with DoC worldwide. Improving understanding and management of patients with DoC requires harmonization of existing datasets, development of registries where none exist and establishment of international clinical trial networks that include patients in all phases along the spectrum of care. The work of international organizations like the Curing Coma Campaign can hopefully minimize international variability in the diagnosis and management of DoC and optimize care.</p></div>","PeriodicalId":20530,"journal":{"name":"Presse Medicale","volume":"52 2","pages":"Article 104162"},"PeriodicalIF":2.7,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10736479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Presse MedicalePub Date : 2023-06-01DOI: 10.1016/j.lpm.2022.104163
Naji Alnagger , Paolo Cardone , Charlotte Martial , Steven Laureys , Jitka Annen , Olivia Gosseries
{"title":"The current and future contribution of neuroimaging to the understanding of disorders of consciousness","authors":"Naji Alnagger , Paolo Cardone , Charlotte Martial , Steven Laureys , Jitka Annen , Olivia Gosseries","doi":"10.1016/j.lpm.2022.104163","DOIUrl":"10.1016/j.lpm.2022.104163","url":null,"abstract":"<div><p>Patients with disorders of consciousness (DoC) represent a group of severely brain-injured patients with varying capacities for consciousness in terms of both wakefulness and awareness. The current state-of-the-art for assessing these patients is through standardised behavioural examinations, but inaccuracies are commonplace. Neuroimaging and electrophysiological techniques have revealed vast insights into the relationships between neural alterations, andcognitive and behavioural features of consciousness in patients with DoC. This has led to the establishment of neuroimaging paradigms for the clinical assessment of DoC patients. Here, we review selected neuroimaging findings on the DoC population, outlining key findings of the dysfunction underlying DoC and presenting the current clinical utility of neuroimaging tools. We discuss that whilst individual brain areas play instrumental roles in generating and supporting consciousness, activation of these areas alone is not sufficient for conscious experience. Instead, for consciousness to arise, we need preserved thalamo-cortical circuits, in addition to sufficient connectivity between distinctly differentiated brain networks, underlined by connectivity both within, and between such brain networks. Finally, we present recent advances and future perspectives in computational methodologies applied to DoC, supporting the notion that progress in the science of DoC will be driven by a symbiosis of these data-driven analyses, and theory-driven research. Both perspectives will work in tandem to provide mechanistic insights contextualised within theoretical frameworks which ultimately inform the practice of clinical neurology.</p></div>","PeriodicalId":20530,"journal":{"name":"Presse Medicale","volume":"52 2","pages":"Article 104163"},"PeriodicalIF":2.7,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10740145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
